Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell)
- Generic Name
- Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell)
A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults
Phase 1
Completed
- Conditions
- Poliomyelitis
- Interventions
- Biological: Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio)Biological: Inactivated poliomyelitis vaccine (IPOL)
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- CanSino Biologics Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT06101173
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath